000273935 001__ 273935
000273935 005__ 20250120102327.0
000273935 0247_ $$2doi$$a10.1038/s41531-024-00842-8
000273935 0247_ $$2pmid$$apmid:39663354
000273935 0247_ $$2pmc$$apmc:PMC11634889
000273935 0247_ $$2altmetric$$aaltmetric:171931301
000273935 037__ $$aDZNE-2024-01409
000273935 041__ $$aEnglish
000273935 082__ $$a610
000273935 1001_ $$0P:(DE-2719)9001592$$aLa Vitola, Pietro$$b0$$eFirst author
000273935 245__ $$aMitochondrial oxidant stress promotes α-synuclein aggregation and spreading in mice with mutated glucocerebrosidase.
000273935 260__ $$aLondon [u.a.]$$bNature Publ. Group$$c2024
000273935 3367_ $$2DRIVER$$aarticle
000273935 3367_ $$2DataCite$$aOutput Types/Journal article
000273935 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1734090989_27141
000273935 3367_ $$2BibTeX$$aARTICLE
000273935 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000273935 3367_ $$00$$2EndNote$$aJournal Article
000273935 520__ $$aIn this study, heterozygous expression of a common Parkinson-associated GBA1 variant, the L444P mutation, was found to exacerbate α-synuclein aggregation and spreading in a mouse model of Parkinson-like pathology targeting neurons of the medullary vagal system. These neurons were also shown to become more vulnerable to oxidative and nitrative stress after L444P expression. The latter paralleled neuronal formation of reactive oxygen species and led to a pronounced accumulation of nitrated α-synuclein. A causal relationship linked mutation-induced oxidative/nitrative stress to enhanced α-synuclein aggregation and spreading that could indeed be rescued by neuronal overexpression of mitochondrial superoxide dismutase 2. Further evidence supported a key involvement of mitochondria as sources of reactive oxygen species as well as targets of oxidative and nitrative damage within L444P-expressing neurons. These findings support the conclusion that enhanced vulnerability to mitochondrial oxidative stress should be considered an important mechanism predisposing to pathology conversion in carriers of GBA1 mutations.
000273935 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000273935 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000273935 7001_ $$0P:(DE-2719)9002553$$aSzegoe, Eva$$b1$$udzne
000273935 7001_ $$0P:(DE-2719)9001609$$aPinto-Costa, Rita$$b2
000273935 7001_ $$0P:(DE-2719)2812656$$aRollar, Angela$$b3
000273935 7001_ $$0P:(DE-2719)9001593$$aHarbachova, Eugenia$$b4$$udzne
000273935 7001_ $$00000-0002-3018-3966$$aSchapira, Anthony Hv$$b5
000273935 7001_ $$0P:(DE-2719)2772760$$aUlusoy, Ayse$$b6
000273935 7001_ $$0P:(DE-2719)2481741$$aDi Monte, Donato A$$b7$$eLast author
000273935 773__ $$0PERI:(DE-600)2819218-7$$a10.1038/s41531-024-00842-8$$gVol. 10, no. 1, p. 233$$n1$$p233$$tnpj Parkinson's Disease$$v10$$x2373-8057$$y2024
000273935 8564_ $$uhttps://pub.dzne.de/record/273935/files/DZNE-2024-01409.pdf$$yOpenAccess
000273935 8564_ $$uhttps://pub.dzne.de/record/273935/files/DZNE-2024-01409.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000273935 909CO $$ooai:pub.dzne.de:273935$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000273935 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001592$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000273935 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002553$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000273935 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001609$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000273935 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812656$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000273935 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001593$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000273935 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2772760$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000273935 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2481741$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000273935 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000273935 9141_ $$y2024
000273935 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-29
000273935 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-29
000273935 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-29
000273935 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000273935 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNPJ PARKINSONS DIS : 2022$$d2023-08-29
000273935 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:11:33Z
000273935 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:11:33Z
000273935 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-29
000273935 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-29
000273935 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-29
000273935 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000273935 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:11:33Z
000273935 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-29
000273935 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNPJ PARKINSONS DIS : 2022$$d2023-08-29
000273935 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-29
000273935 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-29
000273935 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-29
000273935 9201_ $$0I:(DE-2719)1013008$$kAG Di Monte$$lNeurodegeneration and Neuroprotection in Parkinson´s Disease$$x0
000273935 980__ $$ajournal
000273935 980__ $$aVDB
000273935 980__ $$aUNRESTRICTED
000273935 980__ $$aI:(DE-2719)1013008
000273935 9801_ $$aFullTexts